Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotoxins: magic bullets or misguided missiles?

E S Vitetta1, P E Thorpe, J W Uhr

  • 1Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas 75235.

Immunology Today
|June 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemical construction of immunotoxins.

Methods in molecular medicine·2011
Same author

Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia.

Leukemia & lymphoma·2006
Same author

A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro.

Bone marrow transplantation·2006
Same author

Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation.

Cytotherapy·2005
Same author

An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory.

Proceedings of the National Academy of Sciences of the United States of America·2004
Same author

Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.

Neoplasma·2003

Immunotoxin therapy development for cancer, AIDS, and autoimmune diseases is slow due to a complex, multi-step process involving basic science, preclinical models, and extensive clinical trials.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Specific killing of tumor cells using immunotoxins was first described 13 years ago.
  • The clinical impact of immunotoxin therapy on cancer, AIDS, and autoimmune diseases remains under evaluation.
  • Translating basic scientific discoveries into clinical applications is a lengthy, multistep process.

Purpose of the Study:

  • To discuss the basic and clinical aspects of immunotoxin therapy development.
  • To explain the challenges and timelines involved in bringing immunotoxin therapies to patients.
  • To highlight the iterative process of immunotoxin design, testing, and clinical evaluation.

Main Methods:

  • Iterative design and redesign of immunotoxin molecules by basic scientists.

Related Experiment Videos

  • In vitro and in vivo efficacy and toxicity studies in experimental models.
  • Human clinical trials for dose regimen optimization and problem identification.

    • Main Results:

    • The development pathway requires extensive preclinical and clinical evaluation.
    • New challenges and issues frequently emerge during human trials.
    • Animal models are used to address problems identified in clinical studies.

    Conclusions:

    • Immunotoxin therapy development is a slow, interdisciplinary process.
    • Successful clinical translation requires continuous refinement based on experimental and clinical data.
    • Further research and development are essential for realizing the potential of immunotoxins in treating major diseases.